TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB). With that new indication, AC-201 is currently under development by Twi in three tracks: type 2 diabetes, gout and now for EB, a debilitating skin condition.